哮喘合并酸反流患者临床采用埃索美拉唑联合莫沙必利治疗后抑酸和肺功能的疗效

doi:10.3877/cma.j.issn.2095-8765.2023.04.004

中华胃食管反流病电子杂志 ›› 2023, Vol. 10 ›› Issue (04) : 181 -186. doi: 10.3877/cma.j.issn.2095-8765.2023.04.004

论著

哮喘合并酸反流患者临床采用埃索美拉唑联合莫沙必利治疗后抑酸和肺功能的疗效

麦热哈巴·哈力克¹, 艾帕都拉·艾斯拉², 赵燕霞¹, 买买提·依斯热依力³, 魏雪梅¹^,^†(

), 克力木·阿不都热依木³

^1. 830001　乌鲁木齐，新疆维吾尔自治区人民医院呼吸与危重症医学中心
^2. 830001　乌鲁木齐，新疆维吾尔自治区人民医院耳鼻喉诊疗中心
^3. 830001　乌鲁木齐，新疆维吾尔自治区人民医院自治区普外微创研究所

收稿日期:2023-04-17 出版日期:2023-11-15
通信作者: 魏雪梅
基金资助:
新疆维吾尔自治区人民医院院内项目(20190420)

Analysis of the efficacy of acid suppression and pulmonary function after clinical treatment with esomeprazole combined with mosapride in patients with asthma combined with acid reflux

Halike Mairehaba·¹, Aisila Aipadula·², Yanxia Zhao¹, Yisireyili Maimaiti·³, Xuemei Wei¹^,^†(), Abudureyimu Kelimu·³

^1. Respiratory and Critical Care Medicine Center, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China
^2. Otolaryngology Diagnosis and Treatment Center, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China
^3. Resaerch Center for Minimally Invasive Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China

Received:2023-04-17 Published:2023-11-15
Corresponding author: Xuemei Wei

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

麦热哈巴·哈力克, 艾帕都拉·艾斯拉, 赵燕霞, 买买提·依斯热依力, 魏雪梅, 克力木·阿不都热依木. 哮喘合并酸反流患者临床采用埃索美拉唑联合莫沙必利治疗后抑酸和肺功能的疗效[J/OL]. 中华胃食管反流病电子杂志, 2023, 10(04): 181-186.

Halike Mairehaba·, Aisila Aipadula·, Yanxia Zhao, Yisireyili Maimaiti·, Xuemei Wei, Abudureyimu Kelimu·. Analysis of the efficacy of acid suppression and pulmonary function after clinical treatment with esomeprazole combined with mosapride in patients with asthma combined with acid reflux[J/OL]. Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition), 2023, 10(04): 181-186.

目的

探讨对于哮喘合并酸反流患者临床采用埃索美拉唑联合莫沙必利治疗后抑酸和肺功能的疗效。

方法

回顾性分析2020年6月至2021年12月在新疆维吾尔自治区人民医院呼吸与危重症医学中心住院的哮喘合并胃食管反流病（GERD）患者（51例），根据治疗方式的不同，进一步分为对照组（给予哮喘常规治疗）和研究组（对照组基础上给予埃索美拉唑联合枸橼酸莫沙必利）。收集患者临床一般信息，肺功能，GERD问卷（GERD-Q），哮喘控制测试（ACT）评分以及呼吸困难量表（mMRC）等相关辅助检查数据。2组患者均进行治疗8周，收集并分析2组患者治疗前后上述指标的改善情况。

结果

研究组改善酸反流症状（GERD-Q）评分、ACT评分以及mMRC评分指标的程度明显优于对照组，差异均有统计学意义（P<0.05）。2组患者治疗前及治疗后经肺功能检查分析发现，与对照组相比，研究组显著改善患者第一秒用力呼气容积/用力肺活量（FEV1/FVC）、氧分压及二氧化碳分压等指标，差异均有统计学意义（P<0.05）。对照组总有效率为64.00%，研究组为88.46%，差异有统计学意义（P<0.05）。

结论

采用埃索美拉唑联合枸橼酸莫沙必利治疗哮喘合并GERD效果优于常规治疗，值得进一步临床推广应用。

关键词: 胃食管反流病, 哮喘, 埃索美拉唑, 莫沙必利, 疗效

Objective

To investigate the efficacy of acid suppression and pulmonary function in patients with asthma combined with acid reflux after clinical treatment with esomeprazole in combination with mosapride.

Method

Patients with asthma combined with GERD (51 cases) hospitalized in the Respiratory and Critical Care Medicine Center of the People's Hospital of Xinjiang Uygur Autonomous Region from June 2020 to December 2021 were retrospectively analyzed and further divided into a control group (given conventional asthma treatment) and a study group (given esomeprazole combined with mosapride citrate on top of the control group) according to the treatment modality. General clinical information, lung function, GERDQ scale, asthma control test (ACT) score and Medical research association dyspnea scale (mMRC) were collected. Patients in both groups were treated for 8 weeks, and the improvement of the above indicators was collected and analyzed before and after treatment in both groups.

Result

The improvement of acid reflux symptoms (GERD-Q) score, ACT score, and mMRC score indicators in the research group was significantly better than that in the control group, and the differences were statistically significant (P<0.05). Two groups of patients underwent pulmonary function analysis before and after treatment, and it was found that compared with the control group, the study group significantly improved lung function indicators: first second forced expiratory volume/forced vital capacity (FEV1/FVC), oxygen partial pressure, and carbon dioxide partial pressure. The differences were statistically significant (P<0.05). The total effective rate of the control group was 64.00%, while that of the study group was 88.46%, with a statistically significant difference (P<0.05).

Conclusion

The use of esomeprazole combined with mosapride citrate in the treatment of asthma combined with GERD is more effective than conventional treatment and deserves further clinical application.

Key words: Gastroesophageal reflux disease, Asthma, Esomeprazole, Mosapride, Curative effect

表1 2组患者一般临床资料比较

组别	例数	性别(男性/女性)	年龄(岁, )	体质量指数(kg/m²)	病程(个月, )
对照组	25	16/9	55.80±6.87	25.34±3.47	8.60±1.29
研究组	26	15/11	57.07±7.19	26.48±3.32	8.11±2.25
χ²/t值		0.213	-0.648	-1.208	0.938
P值		0.645	0.520	0.233	0.353

表1 2组患者一般临床资料比较

组别	例数	性别(男性/女性)	年龄(岁, )	体质量指数(kg/m²)	病程(个月, )
对照组	25	16/9	55.80±6.87	25.34±3.47	8.60±1.29
研究组	26	15/11	57.07±7.19	26.48±3.32	8.11±2.25
χ²/t值		0.213	-0.648	-1.208	0.938
P值		0.645	0.520	0.233	0.353

表2 2组患者治疗前后酸反流和哮喘指标比较（分，

）

组别	例数	GERD-Q评分		ACT评分		mMRC评分
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	25	14.88±2.18	11.28±1.76^a	14.88±2.18	17.28±1.93^a	2.96±0.78	1.76±0.72^a
研究组	26	14.19±1.87	9.76±1.47^a	14.50±1.86	21.19±3.36^a	3.00±0.69	1.19±0.691^a
t值		1.207	3.316	0.670	-0.507	-0.193	2.860
P值		0.233	0.002	0.506	0.001	0.844	0.006

表2 2组患者治疗前后酸反流和哮喘指标比较（分，

）

组别	例数	GERD-Q评分		ACT评分		mMRC评分
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	25	14.88±2.18	11.28±1.76^a	14.88±2.18	17.28±1.93^a	2.96±0.78	1.76±0.72^a
研究组	26	14.19±1.87	9.76±1.47^a	14.50±1.86	21.19±3.36^a	3.00±0.69	1.19±0.691^a
t值		1.207	3.316	0.670	-0.507	-0.193	2.860
P值		0.233	0.002	0.506	0.001	0.844	0.006

表3 2组患者治疗前后肺功能指标比较（

）

组别	例数	FEV1/FVC（%）		PaO₂（mmHg）		PaCO₂（mmHg）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	25	65.48±5.92	76.12±6.13^a	63.32±7.78	83.62±4.47^a	50.76±4.51	39.48±3.73^a
研究组	26	67.42±6.69	79.53±4.30^a	65.53±8.23	86.11±3.71^a	49.23±5.14	36.92±3.27^a
t值		-1.095	-2.307	-0.985	-2.168	1.128	2.609
P值		0.279	0.025	0.330	0.035	0.265	0.012

表3 2组患者治疗前后肺功能指标比较（

）

组别	例数	FEV1/FVC（%）		PaO₂（mmHg）		PaCO₂（mmHg）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	25	65.48±5.92	76.12±6.13^a	63.32±7.78	83.62±4.47^a	50.76±4.51	39.48±3.73^a
研究组	26	67.42±6.69	79.53±4.30^a	65.53±8.23	86.11±3.71^a	49.23±5.14	36.92±3.27^a
t值		-1.095	-2.307	-0.985	-2.168	1.128	2.609
P值		0.279	0.025	0.330	0.035	0.265	0.012

表4 2组患者治疗效果比较 [例(%)]

组别	例数	痊愈	有效	无效	总有效率
对照组	25	7(28.00)	9(36.00)	9(36.00)	16(64.00)
研究组	26	13(50.00)	10(38.46)	3(11.54)^a	23(88.46)^a

表4 2组患者治疗效果比较 [例(%)]

组别	例数	痊愈	有效	无效	总有效率
对照组	25	7(28.00)	9(36.00)	9(36.00)	16(64.00)
研究组	26	13(50.00)	10(38.46)	3(11.54)^a	23(88.46)^a

1	Sundbom F, Janson C, Ljunggren M, et al. Asthma and asthma-related comorbidity: effects on nocturnal oxygen saturation[J]. J Clin Sleep Med, 2022, 18(11):2635-2641.
2	Martinucci I, Albano E, Marchi S, et al. Extra-esophageal presentation of gastroesophageal reflux disease: new understanding in a new era[J]. Minerva Gastroenterol Dietol, 2017, 63(3):221-234.
3	Kopsaftis Z, Yap HS, Tin KS, et al. Pharmacological and surgical interventions for the treatment of gastro-oesophageal reflux in adults and children with asthma[J]. Cochrane Database Syst Rev, 2021, 5(5):CD001496.
4	中华医学会消化病学分会. 2014年中国胃食管反流病专家共识意见[J]. 中华消化杂志,2014,34(10):649-661.
5	Flores L, Krause C, Pokala B, et al. Novel therapies for gastroesophageal reflux disease[J]. Curr Probl Surg, 2019, 56(12):100692.
6	Yu Y, Wen S, Wang S, et al. Reflux characteristics in patients with gastroesophageal reflux-related chronic cough complicated by laryngopharyngeal reflux[J].Ann Transl Med, 2019, 7(20):529.
7	Nazemiyeh M, Nouri-Vaskeh M, Somi MH, et al. Lung function parameters in patients with gastroesophageal reflux without respiratory symptoms: a case-control study[J].Gastroenterol Hepatol Bed Bench, 2019, 12(4):287-291.
8	杨凡,龚瑞雪. 埃索美拉唑联合枸橼酸莫沙必利对哮喘合并胃食管反流患者肺功能的影响[J]. 实用临床医药杂志,2016,20(13):155-156,162.
9	刘廷敏, 成永清. 消化内科胃食管反流病的临床治疗效果[J].中国城乡企业卫生, 2019, 34(4):17-21.
10	许玉双, 张翠萍, 杨鑫. 胃食管反流病相关肺损伤与肺癌发病研究进展[J]. 中国实用内科杂志, 2018, 38(10):961-963.
11	Lin S, Li H, Fang X. esophageal motor dysfunctions in gastroesophageal reflux disease and therapeutic perspectives[J]. J Neurogastroenterol Motil, 2019, 25(4):499-507.
12	王艳, 林琳, 姜柳琴. 胃食管反流病的食管动力异常研究进展[J]. 胃肠病学, 2019,24(5):311-314.
13	黎丽群, 谢胜, 陈明冰, 等. GerdQ量表对胃食管反流性疾病诊断价值的Meta分析[J].中国循证医学杂志, 2019, 19(8):62-65.
14	Hillman L, Yadlapati R, Thuluvath AJ, et al. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease[J]. Dis Esophagus, 2017, 30(9):1-15.
15	Qi Q, Wang R, Liu L, et al. Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophagealreflux disease: a systematic review and meta-analysis[J]. Int J Clin Pharmacol Ther, 2015, 53(10):803-810.
16	Komura M, Kanamori Y, Tanaka Y, et al. Mosapride for gastroesophageal reflux disease in neurologically impaired patients[J]. Pediatr Int, 2017, 59(3):347-351.
17	Fernando T, Goldman RD. Management of gastroesophageal reflux disease in pediatric patients with cerebral palsy[J]. Can Fam Physician, 2019, 65(11):796-798.
18	Zhuang ZH, Zou FM, Tang DP, et al. The 5-HT4 receptor agonist mosapride attenuates inflammation of reflux esophagitis [J]. Hepatogastroe nterology, 2014 ,61(129):115-119.
19	Liu Q, Feng CC, Wang EM, et al. Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: a systematic review [J]. World J Gastroenterol, 2013, 19(47):9111-9118.
20	佐拉木·买买提, 薛克栋. 胃食管反流病引起呼吸及循环系统急症的临床症状特点分析[J/OL]. 中华胃食管反流病电子杂志, 2017, 4(2):72-74.
21	崔亚, 姜礼双, 卜平.胃食管反流病发病机制的研究进展[J].中国实用医刊, 2018, 45(12):122-126,封3.
22	Piyasena IN, Jayasinghe JA. Mosapride (5HT4 agonist) in the treatment of blepharospasm[J]. Ceylon Med J, 2014, 59(1):26-27.
23	Kiljander TO. The role of proton pump inhibitors in the management of gastroesophageal reflux disease-related asthma and chronic cough[J]. Am J Med, 2003,115 Suppl 3A:65S-71S.
24	Kanemitsu Y, Kurokawa R, Takeda N, et al. Clinical impact of gastroesophageal reflux disease in patients with subacute/chronic cough[J]. Allergol Int, 2019, 68(4):478-485.
25	Kazyulin AN, Dicheva DT, Parcvania-Vinogradova EV, et al. Methodological features of the pH-metry in patients with a combination of gastroesophageal reflux disease and bronchial asthma[J]. Eksp Klin Gastroenterol, 2016(6):100-104.
26	Derbak M, Boldizhar O, Sirchak Y, et al. Combined course of bronchial asthma and gastroesophageal reflux disease: its clinical, functional peculiarities, and mechanisms of its correction[J]. Georgian Med News, 2017(272):69-74.

[1]	张启龙, 柳亿, 卢会丽, 罗慧, 李成林, 王菁, 王辉. 奥妥珠单抗治疗磷脂酶A2受体相关膜性肾病的疗效与安全性：单中心回顾性分析[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(05): 379-384.
[2]	刘琴, 刘瀚旻, 谢亮. 基质金属蛋白酶在儿童哮喘发生机制中作用的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 564-568.
[3]	王杰, 袁泉, 王玥琦, 乔佳君, 谭春丽, 夏仲元, 刘守尧. 溃疡油在糖尿病足溃疡治疗中的应用效果及安全性观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 480-484.
[4]	聂生军, 王钰, 王毅, 鲜小庆, 马生成. 复方倍他米松局部注射联合光动力疗法治疗小型瘢痕疙瘩的临床疗效观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(05): 404-410.
[5]	莫淇舟, 苏劲, 黄健, 李健维, 李思宁, 柳建军. 智能控压输尿管软镜碎石吸引取石术在直径10～25 mm上尿路结石中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 497-502.
[6]	李海云, 赵敏娴, 申英末, 杨慧琪. 胃底折叠术预防食管裂孔疝术后并发症的研究进展[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 485-490.
[7]	玉素江·图荪托合提, 韩琦, 麦麦提艾力·麦麦提明, 黄旭东, 王浩, 克力木·阿不都热依木, 艾克拜尔·艾力. 腹腔镜袖状胃切除或联合食管裂孔疝修补术对肥胖症合并胃食管反流病的中期疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 501-506.
[8]	任传富, 杨志, 徐恩, 何梓芸, 罗板鑫, 陈新, 夏雪峰. 腹腔镜疝修补术联合胃底折叠术治疗食管裂孔疝合并胃食管反流病40 例临床分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 507-511.
[9]	李义亮, 苏拉依曼·牙库甫, 麦麦提艾力·麦麦提明, 克力木·阿不都热依木. 机器人与腹腔镜食管裂孔疝修补术联合Nissen 胃底折叠术短期疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 512-517.
[10]	周艳, 李盈, 周小兵, 程发辉, 何恒正. 不同类型补片联合Nissen 胃底折叠术修补食管裂孔疝的疗效及复发潜在危险因素[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 528-533.
[11]	梁艳娉, 列诗韵, 王艺穗, 吴晓瑛, 林颖. 基于内镜操作细节记录系统构建胃底静脉曲张内镜下组织胶注射术的标准化管理方案[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 705-709.
[12]	陈杰, 武明胜, 李一金, 李虎, 向源楚, 荣新奇, 彭健. 低位直肠癌冷冻治疗临床初步分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 494-498.
[13]	史彬, 司远. 益气和络方联合缬沙坦治疗气阴两虚兼血瘀证IgA 肾病的疗效观察[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 306-312.
[14]	韩俊岭, 王刚, 马厉英, 连颖, 徐慧. 维生素D 联合匹维溴铵治疗腹泻型肠易激综合征患者疗效及对肠道屏障功能指标的影响研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 560-564.
[15]	阳跃, 庹晓晔, 崔子豪, 欧阳四民, 林海阳, 胡景宇, 胡银, 李涛, 赵景峰, 郝岱峰, 冯光. 改良“阅读者”皮瓣修复骶尾部压疮的疗效[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 751-755.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Analysis of the efficacy of acid suppression and pulmonary function after clinical treatment with esomeprazole combined with mosapride in patients with asthma combined with acid reflux

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Analysis of the efficacy of acid suppression and pulmonary function after clinical treatment with esomeprazole combined with mosapride in patients with asthma combined with acid reflux